Blockage of arterial blood vessels caused by atherosclerosis is largely responsible for heart attacks and strokes, which are the most common causes of death worldwide.
Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today that it will present preclinical data of its lead asset, ACTM-838, in a poster presentation at the 2023 38th Society for Immunotherapy of Cancer (SITC) Annual Meeting in San Diego, California. The presentation will feature data examining the tumor-specific enrichment and payload delivery of ACTM-838 in multiple tumor models.
Study lead Professor Johann De Bono said: This is tremendously exciting - and it suggests we have an entirely new way to treat prostate cancer on the horizon.
TREMFYA® (guselkumab) Provides Sustained Improvements Across All Minimal Disease Activity Domains for Adults Living with Active Psoriatic Arthritis in Phase 3b Trial webwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from webwire.com Daily Mail and Mail on Sunday newspapers.
SPRING HOUSE, PENNSYLVANIA, May 31, 2023 - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 3b COSMOS clinical trial showing that treatment. | May 31, 2023